Humoral Immune Response After Different SARS-CoV-2 Vaccination Regimens

Overview

Journal BMC Med

Publisher Biomed Central

Specialty General Medicine

Date 2022 Jan 21

PMID 35057798

Authors

Ruben Rose

Franziska Neumann

Olaf Grobe

Thomas Lorentz

Helmut Fickenscher

Andi Krumbholz

Affiliations

Soon will be listed here.

Abstract

Background: The humoral immune response after primary immunisation with a SARS-CoV-2 vector vaccine (AstraZeneca AZD1222, ChAdOx1 nCoV-19, Vaxzevria) followed by an mRNA vaccine boost (Pfizer/BioNTech, BNT162b2; Moderna, m-1273) was examined and compared with the antibody response after homologous vaccination schemes (AZD1222/AZD1222 or BNT162b2/BNT162b2).

Methods: Sera from 59 vaccinees were tested for anti-SARS-CoV-2 immunoglobulin G (IgG) and virus-neutralising antibodies (VNA) with three IgG assays based on (parts of) the SARS-CoV-2 spike (S)-protein as antigen, an IgG immunoblot (additionally contains the SARS-CoV-2 nucleoprotein (NP) as an antigen), a surrogate neutralisation test (sVNT), and a Vero-cell-based virus-neutralisation test (cVNT) with the B.1.1.7 variant of concern (VOC; alpha) as antigen. Investigation was done before and after heterologous (n = 30 and 42) or homologous booster vaccination (AZD1222/AZD1222, n = 8/9; BNT162b2/BNT162b2, n = 8/8). After the second immunisation, a subgroup of 26 age- and gender-matched sera (AZD1222/mRNA, n = 9; AZD1222/AZD1222, n = 9; BNT162b2/BNT162b2, n = 8) was also tested for VNA against VOC B.1.617.2 (delta) in the cVNT. The strength of IgG binding to separate SARS-CoV-2 antigens was measured by avidity.

Results: After the first vaccination, the prevalence of IgG directed against the (trimeric) SARS-CoV-2 S-protein and its receptor binding domain (RBD) varied from 55-95% (AZD1222) to 100% (BNT162b2), depending on the vaccine regimen and the SARS-CoV-2 antigen used. The booster vaccination resulted in 100% seroconversion and the occurrence of highly avid IgG, which is directed against the S-protein subunit 1 and the RBD, as well as VNA against VOC B.1.1.7, while anti-NP IgGs were not detected. The results of the three anti-SARS-CoV-2 IgG tests showed an excellent correlation to the VNA titres against this VOC. The agreement of cVNT and sVNT results was good. However, the sVNT seems to overestimate non- and weak B.1.1.7-neutralising titres. The anti-SARS-CoV-2 IgG concentrations and the B.1.1.7-neutralising titres were significantly higher after heterologous vaccination compared to the homologous AZD1222 scheme. If VOC B.1.617.2 was used as antigen, significantly lower VNA titres were measured in the cVNT, and three (33.3%) vector vaccine recipients had a VNA titre < 1:10.

Conclusions: Heterologous SARS-CoV-2 vaccination leads to a strong antibody response with anti-SARS-CoV-2 IgG concentrations and VNA titres at a level comparable to that of a homologous BNT162b2 vaccination scheme. Irrespective of the chosen immunisation regime, highly avid IgG antibodies can be detected just 2 weeks after the second vaccine dose indicating the development of a robust humoral immunity. The reduction in the VNA titre against VOC B.1.617.2 observed in the subgroup of 26 individuals is remarkable and confirms the immune escape of the delta variant.

Citing Articles

Mechanistic models of humoral kinetics following COVID-19 vaccination.

Stocks D, Thomas A, Finn A, Danon L, Brooks-Pollock E J R Soc Interface. 2025; 22(222):20240445.

PMID: 39876790 PMC: 11775660. DOI: 10.1098/rsif.2024.0445.

Longitudinal analysis of SARS-CoV-2 IgG antibody durability in Puerto Rico.

Madewell Z, Graff N, Lopez V, Rodriguez D, Wong J, Maniatis P Sci Rep. 2024; 14(1):30743.

PMID: 39730470 PMC: 11681247. DOI: 10.1038/s41598-024-80465-4.

Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.

Colton H, Barratt N, Temperton N, Hornsby H, Angyal A, Grouneva I Br J Haematol. 2024; 205(6):2206-2218.

PMID: 39551718 PMC: 11637739. DOI: 10.1111/bjh.19874.

Longitudinal Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Immunity Over 2 Years Following Vaccination and Infection.

Juhl A, Dietz L, Sogaard O, Reekie J, Nielsen H, Johansen I J Infect Dis. 2024; 230(3):e605-e615.

PMID: 38687181 PMC: 11420770. DOI: 10.1093/infdis/jiae215.

Immunogenicity Assessment of the SARS-CoV-2 Protein Subunit Recombinant Vaccine (CoV2-IB 0322) in a Substudy of a Phase 3 Trial in Indonesia.

Shakinah S, Aini M, Sekartini R, Soedjatmiko , Medise B, Gunardi H Vaccines (Basel). 2024; 12(4).

PMID: 38675753 PMC: 11053672. DOI: 10.3390/vaccines12040371.

References

Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C . Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021; 9(11):1255-1265. PMC: 8360702. DOI: 10.1016/S2213-2600(21)00357-X. View

Wall E, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C . Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021; 397(10292):2331-2333. PMC: 8175044. DOI: 10.1016/S0140-6736(21)01290-3. View

He Q, Mao Q, An C, Zhang J, Gao F, Bian L . Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect. 2021; 10(1):629-637. PMC: 8009122. DOI: 10.1080/22221751.2021.1902245. View

Klasse P, Nixon D, Moore J . Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. Sci Adv. 2021; 7(12). PMC: 7978427. DOI: 10.1126/sciadv.abe8065. View

Gross R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D . Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. EBioMedicine. 2021; 75:103761. PMC: 8682749. DOI: 10.1016/j.ebiom.2021.103761. View

Frieman M, Harris A, Herati R, Krammer F, Mantovani A, Rescigno M . SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors. EBioMedicine. 2021; 68:103401. PMC: 8149267. DOI: 10.1016/j.ebiom.2021.103401. View

Borobia A, Carcas A, Perez-Olmeda M, Castano L, Bertran M, Garcia-Perez J . Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021; 398(10295):121-130. PMC: 8233007. DOI: 10.1016/S0140-6736(21)01420-3. View

Liu X, Shaw R, Stuart A, Greenland M, Aley P, Andrews N . Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021; 398(10303):856-869. PMC: 8346248. DOI: 10.1016/S0140-6736(21)01694-9. View

Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S . Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021; 27(9):1530-1535. PMC: 8440177. DOI: 10.1038/s41591-021-01464-w. View

10.

Hu B, Guo H, Zhou P, Shi Z . Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2020; 19(3):141-154. PMC: 7537588. DOI: 10.1038/s41579-020-00459-7. View

11.

Krammer F . SARS-CoV-2 vaccines in development. Nature. 2020; 586(7830):516-527. DOI: 10.1038/s41586-020-2798-3. View

12.

Normark J, Vikstrom L, Gwon Y, Persson I, Edin A, Bjorsell T . Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination. N Engl J Med. 2021; 385(11):1049-1051. PMC: 8314734. DOI: 10.1056/NEJMc2110716. View

13.

Earle K, Ambrosino D, Fiore-Gartland A, Goldblatt D, B Gilbert P, Siber G . Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021; 39(32):4423-4428. PMC: 8142841. DOI: 10.1016/j.vaccine.2021.05.063. View

14.

Stromer A, Rose R, Schafer M, Schon F, Vollersen A, Lorentz T . Performance of a Point-of-Care Test for the Rapid Detection of SARS-CoV-2 Antigen. Microorganisms. 2020; 9(1). PMC: 7823488. DOI: 10.3390/microorganisms9010058. View

15.

Jalkanen P, Kolehmainen P, K Hakkinen H, Huttunen M, Tahtinen P, Lundberg R . COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun. 2021; 12(1):3991. PMC: 8239026. DOI: 10.1038/s41467-021-24285-4. View

16.

Kyriakidis N, Lopez-Cortes A, Gonzalez E, Grimaldos A, Prado E . SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021; 6(1):28. PMC: 7900244. DOI: 10.1038/s41541-021-00292-w. View

17.

Kristiansen P, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K . WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021; 397(10282):1347-1348. PMC: 7987302. DOI: 10.1016/S0140-6736(21)00527-4. View

18.

Cines D, Bussel J . SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. N Engl J Med. 2021; 384(23):2254-2256. PMC: 8063912. DOI: 10.1056/NEJMe2106315. View

19.

Severance E, Bossis I, Dickerson F, Stallings C, Origoni A, Sullens A . Development of a nucleocapsid-based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a U.S. metropolitan population. Clin Vaccine Immunol. 2008; 15(12):1805-10. PMC: 2593164. DOI: 10.1128/CVI.00124-08. View

20.

Bonelli F, Blocki F, Bunnell T, Chu E, De La O A, Grenache D . Evaluation of the automated LIAISON SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies. Clin Chem Lab Med. 2021; 59(8):1463-1467. DOI: 10.1515/cclm-2021-0023. View